The present disclosure relates to a hashish product having improved consistency, texture and/or appearance. For example, the hashish product may include a cohesive mass of isolated trichomes and a moisture content that is distributed throughout in the cohesive mass. The present disclosure also relates to a process for making the hashish product which includes incorporating water in a mass of isolated trichomes prior to pressing same.

The present disclosure relates to a hashish product having improved consistency, texture and/or appearance. For example, the hashish product may include a cohesive mass of isolated trichomes and a moisture content that is distributed throughout in the cohesive mass. The present disclosure also relates to a process for making the hashish product which includes incorporating water in a mass of isolated trichomes prior to pressing same.

In some embodiments provided herein is a method of treating pain associated with cesarean section surgery in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

In some embodiments provided herein is a method of treating pain associated with cesarean section surgery in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.

The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.

The present invention provides a composition comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients for regenerating a growth plate. The composition for regenerating a growth plate can inhibit bone bridge formation in a growth plate injury region without a scaffold and differentiate to a growth plate cartilage tissue to effectively fill and regenerate the injured region therewith, whereby the regenerated growth plate tissue can recover growth ability. In addition, the composition is compatible with and safe to biological tissues and is characterized by high reproducibility and homogeneity.

The present invention provides a composition comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients for regenerating a growth plate. The composition for regenerating a growth plate can inhibit bone bridge formation in a growth plate injury region without a scaffold and differentiate to a growth plate cartilage tissue to effectively fill and regenerate the injured region therewith, whereby the regenerated growth plate tissue can recover growth ability. In addition, the composition is compatible with and safe to biological tissues and is characterized by high reproducibility and homogeneity.

The present invention relates to the field of medical care, and it relates to the application of alkaloids and volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla in the preparation of medicines or health products for treating influenza or infectious diseases caused by viruses or fungi; especially, it relates to new use of the alkaloids and volatile oils contained in raw materials such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia and other plants in the preparation of drugs or health products for treating influenza or infectious diseases caused by influenza viruses (including HN avian influenza), coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Histoplasma capsulatum, etc.

The present invention relates to the field of medical care, and it relates to the application of alkaloids and volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla in the preparation of medicines or health products for treating influenza or infectious diseases caused by viruses or fungi; especially, it relates to new use of the alkaloids and volatile oils contained in raw materials such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia and other plants in the preparation of drugs or health products for treating influenza or infectious diseases caused by influenza viruses (including HN avian influenza), coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Histoplasma capsulatum, etc.